Overview

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Status:
Not yet recruiting
Trial end date:
2022-12-08
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Incyte Corporation